drugset / Trial / NCT02206308
Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether SCT400 is safe and effective in the treatment of B-cell Non Hodgkin's lymphoma
Timeline
- Start
- 2012-05
- Primary completion
- 2013-07
- Completion
- 2013-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ripertamab | Monoclonal antibody | 250 mg/m2 | — |
| Subject | ripertamab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | ripertamab | Monoclonal antibody | 500 mg/m2 | — |